chartexchange

Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026

GlobeNewswire Inc. | Oct 15, 2026 7:00 AM EDT

Novel oral liquid formulation  of SER-428 is designed for patients who cannot take oral capsules, including critically ill patients receiving nutrition via feeding tube

Read original article